PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITIONPeptides, peptidomimetics and derivatives thereof of the following general formula I: H2N-GHRPX1X2X3-β-X4X5X6X7X8X9X10-X11 (I), in which X1 - X10 denote one of the 20 genetically coded amino acids, wherein X8, X9 and X10 individually or jointly may also denote a single chemical bond - X11 denotes OR1 in which R1 equals hydrogen or (C1 - C10) alkyl, NR2R3 with R2 and R3 are equal or different and denote hydrogen, (C1 - C10) alkyl or a residue -W-PEG5-60K, in which the PEG residue is attached via a suitable spacer W to the N-atom, or a residue NH-Y-Z-PEG5-60K, in which Y denotes a single chemical bond or a genetically coded amino acids from the group S, C, K or R and in which Z denotes a spacer, via which a polyethylene glycol (PEG)-residue can be attached, as well as their physiologically acceptable salts, and in which additionally β denotes an amino acid, whether genetically coded or not, or a peptidomimetic element, which have the additional property of inducing a bend or turn in the peptide backbone. Such amino acids include without limitation L-proline, D-proline, L-hydroxyproline, D-hydroxyproline, L-(O-benzyl)-hydroxyproline, D-(O-benzyl)-hydroxyproline, L-(O-tert. butyl)-hydroxyproline, 4-(O-2-naphtyl)-hydroxyproline, 4-(O-2-naphtyl-methyl)-hydroxyproline, 4-(O-phenyl)-hydroxyproline, 4-(4-phenyl-benzyl)-proline, cis-3-phenyl- proline, cis-4-phenyl-proline, trans-4-phenyl-proline, cis-5-phenyl-proline, trans-5-phenyl-proline, 4-benzyl-proline, 4-bromobenzyl-proline, 4-cyclohexyl-proline, 4-fluor-proline, L-tetrahydroisoquinoline-2-carboxylic acid (L-Tic), all diastereomers of octahydro-indole-2-carboxylic acid (Oic), and all diastereomers of 1-aza-bicyclo[3,3,0]octane-2-carboxylic acid or a residue selected from a group of peptidomimetic residues.Peptides, peptidomimetics and derivatives thereof of the following general formula I:H2N-GHRPX1X2X3-P-X4X5X6X7X8X9X1O-XH (I), in whichX1 - X10 denote one of the 20 genetically coded amino acids, wherein X8, X9 and X10 individually or jointly may also denote a single chemical bondXi i denotes OR1 in which R1 equals hydrogen or (C1 - C1O ) alkyl,NR2R3 with R2 and R3 are equal or different and denote hydrogen, (Ci - do) alkyl or a residue-W-PEG5-6OK , in which the PEG residue is attached via a suitable spacer W to the N-atom, ora residueNH-Y-Z-PEG5-60K ,in whichY denotes a single chemical bond or a genetically coded amino acids from the group S, C, K or R and in whichZ denotes a spacer, via which a polyethylene glycol (PEG)-residue can be attached, as well as their physiologically acceptable salts,and in which additionallyP denotes an amino acid, whether genetically coded or not, or a peptidomimetic element, which have the additional property of inducing a bend or turn in the peptide backbone, said amino acids include without limitation L-proline, D-proline, L-hydroxyproline, D-hydroxyproline, L-(O-benzyl)-hydroxyproline, D-(O-benzyl)-hydroxyproline, L-(O-tert. butyl)-hydroxyproline, 4-(0-2-naphtyl)-hydroxyproline, 4-(O-2-naphtyl-methyl)- hydroxyproline, 4-(O-phenyl)-hydroxyρroline, 4-(4-phenyl-benzyl)-proline, cis-3-phenyl- proline, cis-4-phenyl-proline, trans-4-phenyl-proline, cis-5-plienyl-proline, trans-5-phenyl- proline, 4-benzyl-proline, 4-bromobenzyl-proline, 4-cyclohexyl-proline, 4-fluor-proline, L- tetrahydroisoquinoline-2-carboxylic acid (L-Tic), all diastereomers of octahydro-indole-2- carboxylic acid (Oic), and all diastereomers of l-aza-bicyclo[3,3,0]octane-2-carboxylic acid or a residue selected from the group of:s-2-arainocyclopentane carboxylic acid (cis-Acpc)(1R,2R)- (2-aminocyclopentane carboxylic acid ((1R,2R)-Acpc) (1S,2S)- (2-aminocyclopentane carboxylic acid ((lS,2S)-Acpc)1-aminomethyl-cyclohexane acetic acid (1-Achc)ino-l-carboxymethyl-pyridin-2-one (Acpo) l-amino-cyclobutane-carboxylic acid (l-Acbc) 1-amino-cycloliexane-carboxylic acid (1-Achc) cis-4-amino-cyclohexane-acetic acid (4-Acha)(lR,2R)-2-aminocyclohexane carboxylic acid ((1R,2R)-Achc)(lR,2S)-2-aminocyclohexane carboxylic acid ((1R,2S)-Achc)(lS,2R)-2-aminocyclohexane carboxylic acid ((I S, 2R)- Ache)(lS,2S)-2-aminocyclohexane carboxylic acid ((lS,2S)-Achc)1-amino-cyclopentane carboxylic acid (1-Acpec)1-amino-cyclopropane carboxylic acid (1-Acprc) 4-(2-aminoethyl)-6-dibenzofuranpropionic acid (Aedφ) (R5S)- 1-aminoindane-l-carboxylic acid (1-Aic)2-aminoindane-2-carboxylic acid (2-Aic)2'-(aminomethyl)-biphenyl-2-carboxylic acid (Ambc) 2-aminomethyl-phenylacetic acid (Ampa) 4-amino-tetrahydropyran-4-carboxylic acid (Atpc) (R,S)-2-aminotetraline-2-carboxylic acid (2-Atc) diazabicyclo-[4,3,0]-nonane-l ,4-dione (Acdn) (R)-3-amino-5-carboxyrnethyl-2,3 -dihydro- 1 ,5- benzothiazepin-4(5H)-one (Acbt) (S)-3-amino-5-carboxymethyl-2,3-dihydro-l,5-benzoxazepin- 4(5H)-one (Acbo) ( R,S)-3-amino-l-carboxymethyl-2,3,4,5-tetrahydro-lH-[l]- benzazepin-2-one (1-Acmb) benzazepin-3-one (2-Acmb) 3 -(2-aminoethyl)- 1 -carboxymethyl-quinazoline-2,4-dione (Acq) (2S,5S)-5-amino-l ,2,4,5,6,7-hexahydro-azepino [3,2, 1 -hi]- indole-4-one-2-carboxylic acid (Haic) (R,S)-3-amino-N-l-carboxymethyl-2-oxo-5-cyclohexyl- 1,4-benzodiazepine (Accb) ,4- benzodiazepine (Acpb) (2S,1 laS)-2-amino-10-carboxymethyl-l,2,3,l la-tetrahydro- 10H-ρyrrolo[2,l-c][l,4]-benzodiazepine-5,l 1-dione (PBD) (2S,3'S)-2-(4'-(3'-benzyl-2'-oxo-piperazin-l-yl))-3-ρhenyl- propionic acid (Bppp) 3-carboxymethyl-l-phenyl-l,3,8-triazaspiro[4.5]decan-4-one (Cptd)(R,S)-3-amino-9-Boc-l,2,3,4-tetrahydro-carbazole-3- carboxylic acid (The)exo-amino-bicyclo[2.2.1]heptane-2-exo-carboxylic acid (Abhc)(3 S)-3 -Amino- 1 -carboxymethyl-caprolactam (Accl) (S,S)-(ProLeu)spirolactamePhe (PLSP) 2-Oxo-3-amino-7-thia-l-azabicyclo[4.3.0]nonane-9-carcoxylich acid (BTD)
펩티드, 펩티드모방체 및 그 유도체, 그 제조 방법 및 치료적 및/또는 예방적 활성 약학적 조성물의 제조를 위한 그들의 용도하기 일반식 I의 펩티드, 펩티드모방체 및 그 유도체, 뿐 아니라 이들의 생리학적으로 허용가능한 염으로서,  이 때 X1 - X10 은 20개의 유전적으로 코딩된 아미노산 중 하나를 나타내고, 여기서 X8, X9 및 X10 은 개별적으로 또는 함께 단일 화학 결합을 또한 나타낼 수 있고, X11은 OR1(이 때 R1 은 수소 또는 (C1 - C10)알킬이다), NR2R3(여기서 R2 및 R3은 동일 또는 상이하고, 수소, (C1 - C10) 알킬 또는 잔기 -W-PEG5-60K를 나타내고, 이 때 상기 PEG 잔기는 적절한 스페이서 W를 통해 상기 N-원자에 부착된다), 또는 잔기 NH-Y-Z-PEG5-60K (이 때 Y는 단일 화학 결합 또는 그룹 S, C, K 또는 R로부터의 유전적으로 코딩된 아미노산을 나타내고 또한 Z는 이를 통해 폴리에틸렌 글리콜(PEG)-잔기가 부착될 수 있는 스페이서를 나타낸다)내고, 또한 부가적으로 β는유전적으로 코딩 또는 코딩되지 않은 아미노산, 또는 펩티드모방체 성분을 나타내고, 이는 상기 펩티드 백본을 턴 인하거나 또는 벤드를 유발하는 부가적인 특성을 가진다. 그러한 아미노산은, 이에 한정되는 것은 아니지만, L-프롤린, D-프롤린, L-히드록시프롤린, D-히드록시프롤린, L-(O-벤질)-히드록시프롤린, D-(O-벤질)-히드록시프롤린, L-(O-tert-부틸)-히드록시프롤린, 4-(O-2-나프틸)-히드록시프롤린, 4-(O-2-나프틸-메틸)-히드록시프롤린, 4-(O-페닐)-히드록시프롤린, 4-(4-페닐-벤질)-프롤린, 시스-3-페닐-프롤린, 시스-4-페닐-프롤린, 트랜스-4-페닐-프롤린, 시스-5-페닐-프롤린, 트랜스-5-페닐-프롤린, 4-벤질-프롤린, 4-브로모벤질-프롤린, 4-시클로헥실-프롤린, 4-플루오르-프롤린, L-테트라히드로이소퀴놀린-2-카르복시산 (L-Tic), 옥타히드로-인돌-2-카르복시산(Oic)의 모든 부분입체이성질체, 및 1-아자-비시클로[3,3,0]옥탄-2-카르복시산의 모든 부분입체이성질체, 또는 펩티드모방체 잔기의 그룹에서 선택된 잔기를 포함한다. 하기 일반식 I의 펩티드, 펩티드모방체 및 그 유도체와, 이들의 생리학적으로 허용가능한 염으로서, 이 때, X1 - X10은 20개의 유전적으로 코딩된 아미노산 중 하나를 나타내고, 여기서 X8, X9 및 X10 은 개별적으로 또는 함께 단일 화학 결합을 또한 나타낼 수 있고, X11은 OR1, 이 때 R1 은 수소 또는 (C1 - C10)알킬이고, NR2R3, 여기서 R2 및 R3은 동일 또는 상이하고, 수소, (C1 - C10) 알킬 또는 잔기 -W-PEG5-60K를 나타내고, 이 때 상기 PEG 잔기는 적절한 스페이서 W를 통해 상기 N-원자에 부착되거나, 또는 잔기 NH-Y-Z-PEG5-60K 를 나타내고, 이 때 Y는 단일 화학 결합 또는 그룹 S, C, K 또는 R로부터의 유전적으로 코딩된 아미노산을 나타내고 또한 Z는 스페이서를 나타내고, 이를 통해 폴리에틸렌 글리콜(PEG)-잔기가 부착될 수 있고, 또한 부가적으로 β 는 유전적으로 코딩 또는 코딩되지 않은 아미노산, 또는 펩티드모방체 성분을 나타내고, 상기 펩티드 백본을 턴 인(turn in)하거나 또는 벤드를 유발하는 부가적인 특성을 가지고, 상기 아미노산은, 한정 없이 L-프롤린, D-프롤린, L-히드록시프롤린, D-히드록시프롤린, L-(O-벤질)-히드록시프롤린, D-(O-벤질)-히드록시프롤린, L-(O-tert-부틸)-히드록시프롤린, 4-(O-2-나프틸)-히드록시프롤린, 4-(O-2-나프틸-메틸)-히드록시프롤린, 4-(O-페닐)-히드록시프롤린, 4-(4-페닐-벤질)-프롤린, 시스-3-페닐-프롤린, 시스-4-페닐-프롤린, 트랜스-4-페닐-프롤린, 시스-5-페닐-프롤린, 트랜스-5-페닐-프롤린, 4-벤질-프롤린, 4-브로모벤질-프롤린, 4-시클로헥실-프롤린, 4-플루오르-프롤린, L-테트라히드로이소퀴놀린-2-카르복시산 (L-Tic), 옥타히드로-인돌-2-카르복시산(Oic)의 모든 부분입체이성질체, 및 1-아자-비시클로[3,3,0]옥탄-2-카르복시산의 모든 부분입체이성질체 또는 하기 그룹에서 선택된 잔기를 포함하는 것인, 펩티드, 펩티드모방체 및 그 유도체와, 이들의 생리학적으로 허용가능한 염.